ALINE SGNOLF AYRES

Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 6 de 6
  • conferenceObject
    Early magnetic resonance image (MRI) assessment of diffusion and perfusion in patients (pts) with glioblastoma multiforme (GBM) following chemoradiotherapy (CRT). Is it prognostic?
    (2013) EXMAN, P.; MARQUES, D. F.; SANTANA, I. A.; GARCIA, M. R. T.; PALMA, G. L.; AYRES, A. S.; ZUPPANI, H. B.; FILHO, D. C.; LOUREIRO, L. V. M.; FEHER, O. M.
  • article 1 Citação(ões) na Scopus
    Advances in diffuse glial tumors diagnosis
    (2023) GODOY, Luis Filipe de Souza; PAES, Vitor Ribeiro; AYRES, Aline Sgnolf; BANDEIRA, Gabriela Alencar; MORENO, Raquel Andrade; HIRATA, Fabiana de Campos Cordeiro; SILVA, Frederico Adolfo Benevides; NASCIMENTO, Felipe; CAMPOS NETO, Guilherme de Carvalho; GENTIL, Andre Felix; LUCATO, Leandro Tavares; AMARO JUNIOR, Edson; YOUNG, Robert J.; MALHEIROS, Suzana Maria Fleury
    In recent decades, there have been significant advances in the diagnosis of diffuse gliomas, driven by the integration of novel technologies. These advancements have deepened our understanding of tumor oncogenesis, enabling a more refined stratification of the biological behavior of these neoplasms. This progress culminated in the fifth edition of the WHO classification of central nervous system (CNS) tumors in 2021. This comprehensive review article aims to elucidate these advances within a multidisciplinary framework, contextualized within the backdrop of the new classification. This article will explore morphologic pathology and molecular/genetics techniques (immunohistochemistry, genetic sequencing, and methylation profiling), which are pivotal in diagnosis, besides the correlation of structural neuroimaging radiophenotypes to pathology and genetics. It briefly reviews the usefulness of tractography and functional neuroimaging in surgical planning. Additionally, the article addresses the value of other functional imaging techniques such as perfusion MRI, spectroscopy, and nuclear medicine in distinguishing tumor progression from treatment-related changes. Furthermore, it discusses the advantages of evolving diagnostic techniques in classifying these tumors, as well as their limitations in terms of availability and utilization. Moreover, the expanding domains of data processing, artificial intelligence, radiomics, and radiogenomics hold great promise and may soon exert a substantial influence on glioma diagnosis. These innovative technologies have the potential to revolutionize our approach to these tumors. Ultimately, this review underscores the fundamental importance of multidisciplinary collaboration in employing recent diagnostic advancements, thereby hoping to translate them into improved quality of life and extended survival for glioma patients.
  • article 0 Citação(ões) na Scopus
    Glioneuronal and Neuronal Tumors: Who? When? Where? An Update Based on the 2021 World Health Organization Classification
    (2023) AYRES, A. S.; BANDEIRA, G. A.; FERRACIOLLI, S. F.; TAKAHASHI, J. T.; MORENO, R. A.; GODOY, L. F. de Souza; CASAL, Y. R.; LIMA, L. G. C. A. de; FRASSETO, F. P.; LUCATO, L. T.
    Neuronal and glioneuronal tumors usually have a benign course and may have typical imaging characteristics, allowing their diagnosis based on MR imaging findings. The most common lesions are dysembryoplastic neuroepithelial tumors and gangliogliomas, which have typical imaging characteristics. The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System, recently published in 2021, places greater emphasis on molecular markers to classify tumors of the CNS, leading to extensive changes in the classification of tumors, including neuronal and glioneuronal tumors. The 2021 revision included 3 new tumors types: multinodular and vacuolating neuronal tumor, diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (a provisional type), and myxoid glioneuronal tumor. Following these recent changes in the World Health Organization classification, we aimed to review the main imaging features of these lesions in relation to their histopathologic and molecular features. Learning Objectives: To list the neuronal and glioneuronal tumors; recognize the main imaging findings and histologic characteristics of neuronal and glioneuronal tumors; know the typical location of each neuronal and glioneuronal tumor; and become familiar with the main molecular alterations of neuronal and glioneuronal tumors to better understand their behavior
  • article 4 Citação(ões) na Scopus
    CLIPPERS With Exclusive Extra Pontine Involvement
    (2021) PICARELLI, Helder; YAMAKI, Vitor Nagai; CASAL, Yuri Reis; BRITO, Marcelo Houat de; LIMA, Luiz Guilherme Cernaglia Aureliano de; AYRES, Aline Sgnolf; OLIVEIRA, Marcos Castello Barbosa de
  • bookPart
    Tumores intra e extra-axiais do sistema nervoso central
    (2017) GARCIA, Marcio Ricardo Taveira; HIRATA, Fabiana de Campos Cordeiro; DALPRá, Fábio Augusto Ribeiro; BERTANHA, Renata; AYRES, Aline Sgnolf; LEITE, Claudia da Costa; LUCATO, Leandro Tavares
  • article 0 Citação(ões) na Scopus
    Activity of capecitabine for central nervous system metastases from breast cancer
    (2023) GOUVEIA, Mariana Carvalho; HIDALGO FILHO, Cassio Murilo; MORENO, Raquel Andrade; ALVES, Heitor Castelo Branco Rodrigues; AYRES, Aline Sgnolf; TESTA, Laura; BONADIO, Renata Colombo
    Purpose: Central nervous system (CNS) metastases are a significant burden in breast cancer (BC). Capecitabine is a frequent choice in this scenario, but data supporting its single-agent activity are scarce. We aimed to evaluate the intracranial efficacy of capecitabine in CNS metastases from BC. Methods: This retrospective cohort included patients with CNS metastases from BC treated with capecitabine at a single centre. Study endpoints were intracranial CNS objective response rate (CNS-ORR), intracranial CNS disease control rate (CNS-DCR), intracranial CNS progression-free survival (CNS-PFS) and overall survival (OS).Results: 209 patients were included; 41.6% hormone receptor-positive HER2-negative (HR + HER2-), 33.9% human epidermal growth factor receptor 2 positive (HER2+), and 26.4% triple-negative breast cancer (TNBC). Radiotherapy was performed in 90.4% and CNS surgery in 27.5%. Among patients accessible for intracranial response, 3-month CNS-ORR and CNS-DCR were 41.6% and 81.2%. CNS-ORR was numerically higher among TNBC (61% versus 38% in HR + HER2-BC and 35% in HER2 + BC) (p = 0.194). When considering patients who were not evaluable at 3-month as non-responders, the 3-month CNS-ORR was 19.1% (18.4% in HR + HER2-, 18.3% in HER2+, and 21.6% in TNBC). Nevertheless, TNBC was associated with lower CNS-PFS (p < 0.001) and OS (p < 0.001). Median PFS was 8.3 months in HR + HER2-, 5.0 months in HER2+, and 3.0 months in TNBC. Median OS was 8.7, 9.1 and 4.5 months, respectively.Conclusion: Among patients with BC and CNS metastases accessible for intracranial response at 3 months, intracranial activity was observed with capecitabine. These patients have a poor prognosis regardless of the BC subtype, especially in scenarios where newer therapeutic options are unavailable.